Halting the Rise, Newest Non- Insulin Options for Lowering A1c
|
|
- Noel Boone
- 5 years ago
- Views:
Transcription
1 Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus does not have any actual or potential conflict of interests to disclose and will not be discussing off-label use of medications Goal Upon conclusion of this presentation, attendees will be able to identify the three newer non-insulin agents (SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors) used to treat type 2 diabetes and determine their place in therapy Pharmacists Objectives 1. List three factors to consider when deciding what diabetes medication to recommend for a patient 2. Diagram the different mechanism of action between a GLP-1 agonist and a DPP-4 inhibitor 3. Identify two side effects or contraindications associated with each class of the newer non-insulin agents 4. For a patient with known cardiovascular disease and stage 4 chronic kidney disease, determine if a DPP-4 inhibitor, GLP-1 agonist, and/or a SGLT-2 inhibitor are reasonable treatment recommendations 5. Identify which two GLP-1 agonists are associated with the most weight loss Pharmacy Technician Objectives Diabetes By The Numbers 1. Match the name of diabetes medication to the correct class (SGLT-2 inhibitor, GLP-1 agonist, and DPP-4 inhibitor) 2. List two expected side effects associated with a GLP-1 agonist 3. Explain what new class of diabetes medication has NOT been shown to provide cardiovascular benefit 4. Identify which newer classes of diabetes medication are associated with weight loss In 2015, 30.3 million people were reported to have diabetes in the United States (US) 95% of these are type 2 diabetes 23.8% of these were undiagnosed 1.5 million Americans are diagnosed yearly 7 th leading cause of death in the US in 2015 ~ 1 out of 10 people Centers for Disease Control and Prevention. Atlanta, GA: U.S. Department of Health and Human Services;
2 Top Diabetes Products (Total Sales 2016) Class Brand/Generic Name Class Brand/Generic Name History of Diabetes Treatment Options Insulin GLP-1 Lantus/glargine Januvia/sitagliptin Victoza/liraglutide Insulin Humulin/NPH Tradjenta/linagliptin Galvus/vildagliptin* Insulin Novolog/aspart GLP-1 Trulicity/dulaglutide insulin SU metformin = dipeptidyl peptidase 4 inhibitor GLP-1 = glucagon-like peptide-1 receptor agonist SGLT-2i = sodium-glucose cotransporter-2 inhibitor -glucosidase inhibitors TZD SU = sulfonylurea TZD = thiazolidinedione meglitinide amalylin GLP-1 SGLT-2i Insulin Insulin + Biguanide Humalog/lispro Levemir/detemir JanuMet/ sitagliptin+ metformin Insulin NovologMix/aspart + aspart protamine SGLT-2i + Biguanide InvokaMet/ canagliflozin + metformin SGLT-2i Insulin GLP-1 Alpha-Glucosidase inhibitor Farixa/dapagliflozin Onglyza/saxagliptin Toujeo/glargine (conc) Bydureon/exenatide Precose/Acarbose Nesina/alogliptin Cavailoa, TS. Endotext [Internet] Mar 31; *not FDA approved Source: Evaluate Pharma; Fierce Pharma First line metformin + comprehensive lifestyle Background Side effects ASCVD CHF CKD ASCVD = atherosclerotic cardiovascular disease CHF = chronic heart failure CKD = chronic kidney disease Weight Cost ASCVD - GLP-1 or - SGLT-2i with proven CV benefit If A1c above goal, add - GLP-1* or SGLT-2i* - if not on GLP-1 HF or CKD - SGLT-2i with evidence - GLP-1* if SGLT-2i* not tolerated or indicated If A1c above goal, add - GLP-1* or SGLT-2i* - if not on GLP-1 Hypoglycemia - SGLT-2i, GLP-1, or TZD If A1c above goal, - If on TZD: add SGLT-2i, GLP-1, or - If on SGLT-2i: add GLP-1,, or TZD - If on GLP-1: add SGLT-2i or TZD - If on : add SGLT-2i or TZD No ASCVD or CKD Weight Gain - GLP-1* or SGLT-2i If A1c above goal, add - Follow as outlined above If A1c above goal, add - if not on GLP-1 Cost Issue - SU or TZD If A1c above goal, add - Follow as outlined above If A1c above goal, add - Basal insulin, SGLT-2i or with lowest acquisition cost A1c Agent Patient preference ^avoid TZD and If A1c above goal, add saxagliptin in setting of HF - Follow as outlined above *with proven benefit -summarized chart to focus on newer non-insulin therapies Adapted from American Diabetes Association. Diabetes Care Jan;42(Suppl 1):S94. Overview Mechanisms, efficacy, and side effects Classes SGLT-2 Inhibitors (Oral) GLP-1 Agonists (SQ) DPP-4 Inhibitors (Oral) Cardiovascular outcomes Renal effects Weight effects Cost Canagliflozin (Invokana) Dapagliflozin (Farxiga) Empagliflozin (Jardiance) Ertugliflozin (Steglatro) Albiglutide (Tanzeum) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide ER (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Semaglutide (Ozempic) Alogliptin (Nesina) Linagliptin (Tradjenta) Saxagliptin (Onglyza) Sitagliptin (Januvia) Combination therapy 2
3 SGLT-2 Inhibitors: Mechanism of Action SGLT-2 Inhibitors: flozins Efficacy with metformin Warnings and precautions % A1c reduction Fournier s gangrene Lower limb amputation (canagliflozin) Bone fractures (canagliflozin) Bladder cancer (dapagliflozin) Side effects Genitourinary infections Volume depletion Hypotension Diabetic ketoacidosis (rare) Adapted from Edward C. Chao Clin Diabetes 2014;32:4-11 American Diabetes Association. Diabetes Care 2018 Jan; 41(Supplement 1): S73-S85. Professional Resource, Managmenet of New-Onset Type 2 Diabetes. Pharmacist s letter/prescriber s Letter. October GLP-1 Agonists: Mechanism of Action GLP-1 Agonists: tides Efficacy with metformin Warnings and precautions ~1% A1c reduction Thyroid C-cell tumors (albiglutide, dulaglutide, exenatide ER, liraglutide, semaglutide) Diabetic retinopathy (semaglutide) Possible acute pancreatitis Side effects Injection site reactions Nausea, vomiting, diarrhea Meier JJ. Nat Rev Endocrinol. 2012;8: American Diabetes Association. Diabetes Care 2018 Jan; 41(Supplement 1): S73-S85. Professional Resource, Managmenet of New-Onset Type 2 Diabetes. Pharmacist s letter/prescriber s Letter. October 2016 Twice daily dosing Once daily dosing Weekly Dosing GLP-1 Agonists: Administration Albiglutide (Tanzeum) Dulaglutide (Trulicity) Exenatide (Byetta) Exenatide ER (Bydureon) Liraglutide (Victoza) Lixisenatide (Adlyxin) Semaglutide (Ozempic) DPP-4 Inhibitors: Mechanism of Action enzyme inactivates GLP-1 inhibitors block the inhibitors enzyme block the enzyme Adapted from Strucker DJ. Diabetes Care. 2007;30:
4 DPP-4 Inhibitors: gliptins Efficacy with metformin Warnings and precautions % A1c reduction Side effects Nasopharyngitis Joint pain Potential risk for heart failure: saxagliption, alogliptin Possible acute pancreatitis American Diabetes Association. Diabetes Care 2018 Jan; 41(Supplement 1): S73-S85. Professional Resource, Managmenet of New-Onset Type 2 Diabetes. Pharmacist s letter/prescriber s Letter. October 2016 Patient Case CG is a 67 year-old male with type 2 diabetes currently on metformin 1000mg twice daily. Past medical history includes MI (2 years ago), hypertension (well-controlled), and hyperlipidemia (well-controlled). His most recent A1c is 7.9% with a goal of <7.5%. He would like to try oral therapy before going to an injection. egfr 52 ml/min/1.73m 2, CrCl 63 ml/min, BMI 32 kg/m 2 Which class would you recommend for CG? a) SGLT-2 inhibitor b) GLP-1 agonist c) DPP-4 inhibitor Cardiovascular (CV) Cardiovascular Trials (CVOTs) Phase 2 and 3 trials Inclusion criteria: Patients at higher risk for CV events Sufficient size and duration for meaningful evaluation of CV risk Major adverse cardiac events (MACE) outcomes must include: CV death Non-fatal MI Non-fatal stroke Cefalu WT et al. Diabetes Care Jan; 41(1):14-31 Completed and Ongoing CVOTs TECOS CARMELINA CAROLINA EMPA-REG PIONEER 6 OUTCOME LEADER CANVAS PROGRAM SGLT2i ELIXA SUSTAIN-6 EXSCEL GLP-1 FREEDOM-CVO HARMONY Adapted from Cefalu Jan;41(1):14-31 et al. Dia Care 2018 EMPEROR- Preserved Dapa- CKD Dapa- HF CREDENCE DECLARE VERTIS -TIMI 58 CV EMPEROR- Reduced REWIND EXAMINE SAVOR- TIMI 53 Baseline Characteristics for SGLT-2 Inhibitor Trials EMPA-REG OUTCOME (empagliflozin) CANVAS Program (canagliflozin) N 7,020 10,142 17,160 Median duration (years) Mean age (years) Mean BMI (kg/m 2 ) Previous CV disease (%) > Mean A1c (%) Mean duration of diabetes (years) >10 (>57%) Zinman et al. N Engl J Med Nov 26;373: Ṅeal et al. N Engl J Med 2017; 377: Wiviott, SD et al. N Engl J Med Nov 10. DECLARE-TIMI 58 (dapagliflozin) 4
5 Baseline Characteristics for GLP-1 Agonist ELIXA (lixisenatide) EXSCEL (exenatide) HARMONY (albiglutide) LEADER (liraglutide) N 6,068 14,752 9,463 9,340 3,297 Median duration (years) Mean age (years) Mean BMI (kg/m 2 ) Previous CV disease (%) Mean A1c (%) Mean duration of diabetes (years) SUSTAIN-6 (semaglutide) Baseline Characteristics for DPP-4 Inhibitor CARMELINA (linagliptin) EXAMINE (alogliptin) SAVOR-TIMI 53 (saxagliptin) TECOS (sitagliptin) N 6,979 5,380 16,492 14,671 Median duration (years) Mean age (years) Mean BMI (kg/m 2 ) Previous CV disease (%) Mean A1c (%) Mean duration of diabetes (years) Pfeffer MA et al. N Engl J Med Dec 3;373(23): Holman et al. N Engl J Med Sep 28;377(13): Marso et al. N Engl J Med 2016;375: Holman et al. N Engl J Med Sep 28;377(13): Marso et al. N Engl J Med 2016; 375: Hernandez et al. Lancet Oct 1. pii: S (18)32261-X Rosenstock J et al. JAMA Nov 9. Green JB et al. N Engl J Med Jul 16;373(3): White WB et al. Am Heart J Oct;162(4): Scirica et al. N Engl J Med Oct 3;369(14): ASCVD Benefit Trial (SGLT-2i) EMPA-REG OUTCOME (empagliflozin vs. CANVAS Program (canagliflozin vs. *participants per 1000 patient-years ASCVD Benefit Trial (GLP-1s) EXSCEL (exenatide ER vs. HARMONY (albiglutide vs. LEADER (liraglutide vs. SUSTAIN-6 (semaglutide vs. Primary Composite CV death Fatal/Non-Fatal MI 10.5% vs.12.1% HR % CI % vs. 5.9% HR % CI % vs. 5.4% HR % CI Fatal/Non-Fatal Stroke 3.5% vs. 3.0% HR % CI All Cause Mortality 5.7% vs. 8.3% HR % CI vs 31.5 HR % CI vs HR % CI vs HR % CI vs. 9.6% HR % CI vs HR % CI % vs. 12.2% Primary Composite HR % CI CV death 4.6% vs. 5.2% HR % CI Fatal/Non-Fatal MI 6.6% vs. 6.7% HR % CI Fatal/Non-Fatal Stroke 2.5% vs. 2.9% HR % CI All Cause Mortality 6.9% vs. 7.9% HR % CI % vs. 9% HR % CI % vs. 3% HR % CI % vs. 5% HR % CI % vs. 2% HR % CI % vs. 4% HR % CI % vs. 14.9% HR % CI % vs. 6.0 HR % CI % vs. 7.3% HR % CI % vs. 4.3% HR % CI % vs. 9.6% HR % CI % vs. 8.9% HR % CI % vs. 2.8% HR % CI *non-fatal MI only 2.9% vs 3.9% HR % CI *non-fatal stroke only 1.6% vs. 2.7% HR % CI % vs. 3.6% HR % CI ASCVD Neutral Trial *results not significant DECLARE-TIMI 58 (dapagliflozin vs. ELIXA (lixisenatide vs. CARMELINA (linagliptin vs. EXAMINE (alogliptin vs. SAVOR-TIMI 53 (saxagliptin vs. TECOS (sitagliptin vs. Primary Composite 8.8% vs. 9.4% HR % CI % vs. 13.2% HR % CI % vs. 12.1% HR % CI % vs. 11.8% HR 0.96 Upper level of 95% CI % vs. 7.2% HR % CI % vs. 9.6% HR % CI Systematic Review and Meta-analysis CV death 2.9% vs. 2.9% HR % CI Fatal/Non- *ischemic stroke only Fatal MI 2.7% vs. 2.7% HR % CI Fatal/Non- 4.6% vs. 5.1% Fatal 0.89 Stroke 95% CI All Cause 6.2% vs. 6.6% Mortality HR % CI % vs. 5.2% HR % CI % vs. 8.6% HR % CI % vs. 2.0% HR % CI % vs. 7.4% HR % CI % vs. 7.6% HR % CI % vs. 4.2% HR % CI % vs. 2.5% HR % CI % vs. 10.7% HR % CI % vs. 4.9% HR % CI *non-fatal only 6.9% vs. 6.5% HR % CI *non-fatal only 1.1% vs. 1.2% HR % CI % vs. 6.5% HR % CI % vs. 2.9% HR % CI % vs. 3.4% HR % CI *ischemic stroke only 1.95 vs. 1.7% HR % CI % vs. 4.2% HR % CI % vs. 5.0% HR % CI % vs. 4.3% HR % CI % vs. 2.5% HR % CI % vs. 7.3% HR % CI CV mortality, 56 trials Treatment Comparator HR (95% CI) 1.00 ( ) GLP-1 vs. Control 0.85 ( ) SGLT-2i 0.79 ( ) Control 1.00 ( ) GLP-1 vs ( ) SGLT-2i 0.79 ( ) Control 1.17 ( ) vs. GLP ( ) SGLT-2i 0.93 ( ) Control 1.27 ( ) vs. SGLT-2i 1.27 ( ) GLP ( ) Favors Treatment Favors Comparator Zheng SL et al. JAMA Apr 17;319(15): HR (95% CI) 5
6 Systematic Review and Meta-analysis All-cause mortality, 97 trials Treatment Comparator HR (95% CI) 1.02 ( ) Favors Favors Comparator GLP-1 vs. Control 0.88 ( ) Treatment SGLT-2i 0.80 ( ) Control 0.98 ( ) GLP-1 vs ( ) SGLT-2i 0.78 ( ) Control 1.14 ( ) vs. GLP ( ) SGLT-2i 0.91 ( ) Control 1.25 ( ) vs. SGLT-2i 1.28 ( ) GLP ( ) HR (95% CI) ASCVD CVOTs Summary Superior to placebo for the primary composite outcome Empagliflozin and canagliflozin Liraglutide, semaglutide, and albiglutide Superior to placebo for reduction of CV death and all-cause mortality Empagliflozin Liraglutide Semaglutide is superior to placebo for reduction of non-fatal stroke Albiglutide is superior to placebo for reduction of fatal or nonfatal MI All other trials showed non-inferiority Patient Case CG is a 67 year-old male with type 2 diabetes currently on metformin 1000mg twice daily. Past medical history includes MI (2 years ago), hypertension (wellcontrolled), and hyperlipidemia (well-controlled). His most recent A1c 7.9%, with goal of <7.5%. Desires oral therapy before trying an injection. egfr 52 ml/min/1.73m 2, CrCl 63 ml/min, BMI 32 kg/m 2 What would you recommend for CG? a) Saxagliptin 5mg daily b) Empagliflozin 10mg daily c) Liraglutide 0.6mg daily for one week, then increase to 1.2mg daily d) Dapagliflozin 5mg daily Case continued a) Saxagliptin 5mg daily b) Empagliflozin 10mg daily Shown to be beneficial to reduce CV events for patients with history of ASCVD (MI 2 years ago) c) Liraglutide 0.6mg daily for one week, then increase to 1.2mg daily d) Dapagliflozin 5mg daily Heart Failure (HF) HF Benefit (SGLT-2i) HF Hospitalization EMPA-REG OUTCOME (empagliflozin vs. 2.7% vs. 4.1% HR % CI CANVAS Program (canagliflozin vs. *participants per 1000 patient-years 5.5 vs. 8.7 HR % CI DECLARE-TIMI 58 (dapagliflozin vs. 2.5% vs. 3.3% HR % CI
7 HF Neutral (GLP-1) *results not significant ELIXA (lixisenatide vs. EXSCEL (exenatide ER vs. HARMONY (albiglutide vs. LEADER (liraglutide vs. SUSTAIN-6 (semaglutide vs. HF Risk () SAVOR-TIMI 53 (saxagliptin vs. HF Hospitalization 4.0% vs. 4.2% HR % CI % vs. 3.1% HR % CI Not reported 4.7% vs. 5.3% HR % CI % vs. 3.3% HR % CI HF Hospitalization 3.5% vs. 2.8% HR % CI HF Neutral () *results not significant CARMELINA (linagliptin vs. TECOS (sitagliptin vs. EXAMINE (alogliptin vs. HF Hospitalization 6% vs. 6.5% HR % CI % vs. 3.1% HR % CI % vs. 3.3% HR % CI Systematic Review and Meta-analysis HF events, 58 trials Favors Favors Treatment Comparator HR (95% CI) Treatment Comparator 1.13 ( ) GLP-1 vs. Control 0.93 ( ) SGLT-2i 0.62 ( ) Control 0.88 ( ) GLP-1 vs ( ) SGLT-2i 0.55 ( ) Control 1.08 ( ) vs. GLP ( ) SGLT-2i 0.67 ( ) Control 1.60 ( ) vs. SGLT-2i 1.81 ( ) GLP ( ) HR (95% CI) HF Summary Reduced HF hospitalization Empagliflozin Canagliflozin Dapagliflozin Avoid in the setting of HF Saxagliptin FDA warning: saxaglipitin and alogliptin All other CVOTs showed non-inferiority to placebo in the setting of HF when reported Renal Effects SGLT-2 Inhibitors Evidence From CVOTs Study Outcome Result EMPA-REG OUTCOME (empagliflozin) CANVAS Program (canagliflozin) DECLARE-TIMI 58 (dapagliflozin) Composite: worsening nephropathy New onset macroalbuminuria Doubling of serum creatinine Initiation of renal-replacement therapy Composite: worsening nephropathy New onset macroalbuminuria Doubling of serum creatinine HR 0.61 (95% CI ) HR 0.62 (95% CI ) HR 0.56 (95% CI ) HR 0.45 (95% CI ) HR 0.60 (95% CI ) HR 0.58 (95% CI ) HR 0.50 (95% CI ) Composite: worsening nephropathy HR 0.76 (95% CI ) Perkovic V et al. Lancet Diabetes Endocrinol Sep;6(9):
8 CREDENCE Canagliflozin vs. placebo in patients with diabetic nephropathy Stopped at a planned interim analysis for achieving the primary efficacy endpoint, a composite of end-stage renal disease (ESRD), doubling of serum creatinine, and renal or CV death GLP-1 Agonists Evidence From CVOTs Study Outcome Result LEADER (liraglutide) SUSTAIN-6 (semaglutide) Composite: worsening nephropathy New onset macroalbuminuria Composite: worsening nephropathy New onset macroalbuminuria HR 0.78 (95% CI ) HR 0.74 (95% CI ) HR 0.64 (95% CI ) HR 0.54 (95% CI ) Janssen Research & Development, LLC. 16 Jul available at Accessed 10/29/18. Mann JFE et al. N Engl J Med Aug 31;377(9): DPP-4 Inhibitor Evidence From CVOTs Study Outcome Result SAVOR-TIMI 53 (saxagliptin) CARMELINA (linagliptin) Composite: worsening nephropathy Composite: worsening nephropathy HR 1.08 (95% CI ) HR 0.98 (95% CI ) Renal Dose Adjustments SGLT-2 Inhibitors Agent Renal Dose Adjustment (egfr ml/minute/1.73 m 2 ) Canagliflozin mg daily Dapagliflozin Empagliflozin Ertugliflozin egfr 45-59: max dose 100 mg daily egfr 30-45: do not initiate or continue egfr <30, ESRD, dialysis: contraindicated egfr 30-60: do not initiate or continue egfr <30: contraindicated egfr 30-45: do not initiate or continue egfr <30: contraindicated egfr 30-45: do not initiate or continue egfr <30: contraindicated GLP-1 Agonists Agent Renal Dose Adjustment (CrCl ml/minute; egfr ml/minute/1.73 m 2 ) Albiglutide None Dulaglutide None Exenatide CrCl <30 or ESRD: do not use Exenatide ER CrCl <30 or ESRD: do not use Liraglutide None Lixisenatide egfr <15 or ESRD: do not use Semaglutide None 8
9 DPP-4 Inhibitors Agent Renal Dose Adjustment (CrCl ml/minute; egfr ml/minute/1.73 m 2 ) Alogliptin 25 mg daily Linagliptin Saxagliptin mg daily Sitagliptin 100 mg daily CrCl 30-59: 12.5 mg daily CrCl <30: 6.25 mg daily None egfr <45: 2.5 mg daily egfr 30-44: 50 mg daily egfr <30: 25 mg daily Renal Effects Summary Reduced CKD progression Empagliflozin Canagliflozin Dapagliflozin Reduced macroalbuminiuria Liraglutide Semaglutide Product labels need to be verified to determine renal dose adjustments Patient Case CG returns 4 years later after recently being diagnosed with CHF. Kidney function has declined and metformin has been stopped. Last time you chose to initiate empagliflozin, but know this is no longer an option due to renal function. A1c 8.4%, goal <8%. egfr 29 ml/min/1.73m 2, CrCl 35 ml/min, BMI 34 kg/m 2 PMH: T2DM, MI (6 years ago), CHF, HTN, HLD What would you recommend for CG? a) Saxagliptin 5mg daily b) Canagliflozin 100mg daily c) Liraglutide 0.6mg daily for one week, then increase to 1.2mg daily d) Dapagliflozin 5mg daily Patient Case What would you recommend for CG? a) Saxagliptin 5mg daily b) Canagliflozin 100mg daily c) Liraglutide 0.6mg daily for one week, then increase to 1.2mg daily In patients with CHF or CKD, initiate GLP-1 agonist with CV benefit if unable to initiate SGLT-2i due to renal function or other contraindication d) Dapagliflozin 5mg daily Weight Effects Weight Effects SGLT-2 inhibitors: average weight loss of 1.5-3kg Meta-analysis: kg at 2 years (95% CI to -2.34) GLP-1 agonists: average weight loss of 2-5kg Meta-analysis: -2.9kg at 1.7 years (95% CI -3.6 to -2.2) DPP-4 inhibitors: weight neutral Liu, XY et al. J Diabetes Complications Nov-Dec;29(8): Vilsbøll T et al. BMJ Jan 10;344:d7771. Gurgle, HE et al. Vasc Health Risk Manag. 2016;12:
10 Change in Weight (kg) SUSTAIN 7 AWARD-6 AWARD-1 HARMONY 7 GetGoal-X DURATION-6 DURATION-5 LEAD-6 DURATION-1 ^, ** $ * $ * + ++ * -4.5 Exenatide 2x/day Exenatide weekly Liraglutide Lixisenatide -5 Albiglutide Dulaglutide 1.5 Dulaglutide 0.75 Semaglutide 1.0 Semaglutide * p = not significance; ** not significant between dulaglutide 1.5 and exenatide twice daily; $ -6 p<0.0001; ^p = dulaglutide 0.75 mg vs. exenatide twice daily; + p < ; p = not Dar, S et al. Practical Diabetes 32;8: b. reported for weight difference; ++ p = Pratley RE et al. Lancet Diabetes Endocrinol Apr;6(4): Cost Class Agent AWP ($) for 30 day supply (as of 11/26/2018) SGLT-2 inhibitors Canagliflozin 100 & 300 mg/day Dapagliflozin 5 &10 mg/day Empagliflozin 10 & 25 mg/day Ertugliflozin 5 & 15 mg/day GLP-1 agonists Albiglutide 30 & 50 mg/week Combination Therapies Dulaglutide 0.75 & 1.5 mg/week Exenatide 5 & 10 mcg twice daily Exenatide ER 2 mg/week (all dosage forms) Liraglutide 1.8 mg/day Lixisenatide 20 mcg/day Semaglutide 0.5 & 1 mg/week DPP-4 inhibitors Alogliptin 6.25, 12.5 & 25 mg/day Linagliptin 5 mg/day Saxagliptin 2.5 & 5 mg/day Sitagliptin 25, 50 & 100 mg/day SGLT-2 Inhibitor + DPP-4 Inhibitor SGLT-2 Inhibitor + GLP-1 Agonist Study design Systematic review and meta-analysis of SGLT-2i + vs. SGLT-2i vs. N=4,828 from 14 RCTs Study design Randomized, double blind trial comparing exenatide ER + dapagliflozin vs. exenatide or dapagliflozin alone N=695 for 28 weeks Combo therapy vs. SGLT- 2i vs. A1c from baseline: -0.31% (95% CI to -0.24%) vs % (95% CI -0.80% to -0.61%) Body weight: -0.36kg (95% CI to 1.19kg) vs kg (95% CI to kg) SBP: -0.04mmHg (95% CI to -1.49mmHg) vs. -5.9mmHg (95% CI to -2.95mmHg) Endpoints Combo therapy vs. exenatide or dapagliflozin Primary: change in A1c from baseline Secondary: change from baseline in fasting plasma glucose, weight, systolic blood pressure; weight loss 5%; A1c <7% Primary: -0.4% (95% CI -0.6 to -0.1) -0.6% (95% CI -0.8 to -0.3) Secondary: combo was significantly superior Li D et al. Diabetes Obes Metab Aug;20(8): Frías JP et al. Lancet Diabetes Endocrinol Dec;4(12):
11 SGLT-2 Inhibitor + Insulin GLP-1 Agonist + Insulin Study design Meta-analysis determining safety and efficacy of a SGLT- 2i + insulin vs. insulin + placebo N=4,235 from 7 RCTs Study design Systematic review and meta-analysis comparing GLP-1 + basal insulin vs. other glucose-lowering treatments N=4,348 from 15 RCTs SGLT-2i + insulin vs. placebo Reduction in A1c: -0.56% (95% CI to -0.44%) Weight loss: kg (95% CI to -2.16kg) Insulin dose: units (95% CI to units) Severe Hypoglycemia: RR 1.24 (95% CI 0.91 to 1.70) GLP-1 + insulin vs. other A1c from baseline: -0.44% (95% CI to -0.29%) Compared to basal-bolus: -0.1% (95% CI to 0.02%) Weight loss: kg (95% CI -4.9 to -1.54kg) Compared to basal-bolus: -5.66kg (95% CI -9.8 to -1.51kg) Hypoglycemia: RR 0.99 (95% CI ) Compared to basal-bolus: RR 0.67 (95% CI ) Tang H et al. Diabetes Obes Metab Jan;19(1): Eng et al. Lancet Dec 20;384(9961): Combination Products SGLT-2 inhibitors: canagliflozin + metformin (Invokamet), empagliflozin + linagliptin (Glyxambi), empagliflozin + metformin (Synjardy), ertugliflozin + metformin (Segluromet), ertugliflozin + sitagliptin (Steglujan) GLP-1 agonists: lixisenatide + insulin glargine (Soliqua100/33), liraglutide + insulin degludec (Xulotphy100/3.6) DPP-4 inhibitors: alogliptin + metformin (Kazano), alogliptin + pioglitazone (Oseni), linagliptin + metformin (Jentadueto), linagliptin + empagliflozin (Glyxambi), saxagliptin + metformin (Kombiglyze XR), sitagliptin + metformin (Janumet, Janumet XR) Putting It All Together 2019 ADA STANDARDS OF MEDICAL CARE IN DIABETES American Diabetes Association. Diabetes Care Jan;42(Suppl 1):S7-S193. First line continues to be metformin and comprehensive lifestyle ASCVD: either a SGLT-2i or GLP-1 with proven CVD benefit, if egfr adequate First line continues to be metformin and comprehensive lifestyle HF or CKD: SGLT-2i with evidence of reducing HF and/or CKD progression if egfr adequate OR GLP-1 with proven CVD benefit (after SGLT-2i) If A1c still above goal in 3-6 months If A1c above goal in 3-6 months Consider adding the other class with CVD benefit (SGLT-2i or GLP-1) Add the other class with proven CVD benefit DPP4-i if not on a GLP-1 empagliflozin > canagliflozin liraglutide > semaglutide > exenatide ER (not saxagliptin) in the setting of HF if not on a GLP-1 empagliflozin > canagliflozin liraglutide > semaglutide > exenatide ER 11
12 First line continues to be metformin and comprehensive lifestyle Minimize weight gain or promote weight loss: GLP-1 with good efficacy for weight loss OR SGLT-2i if egfr adequate If A1c above goal in 3-6 months Add agent listed above If A1c above goal in 3-6 months, if not on GLP-1 semaglutide > liraglutide > dulaglutide > exenatide > lixisenatide Dual and Triple Therapy Continue metformin unless contraindicated or no longer tolerated Consider dual therapy in newly diagnosed type 2 diabetes when A1c 1.5% above goal If injectable needed to lower glucose, GLP-1 agonists are preferred over insulin in most cases Consider insulin initiation if evidence of ongoing catabolism, symptomatic hyperglycemia, or very high A1c (>10%) or blood glucose levels ( 300 mg/dl) Overall Summary Class Efficacy Warnings CV outcomes Renal effects Weight change Cost Questions SGLT-2i Intermediate Fournier s gangrene Amputation: canagliflozin Bone fx: canagliflozin Bladder cancer: dapagliflozin GLP-1 High Thyroid C-cell tumor: albiglutide, dulaglutide, exenatide ER, liraglutide Retinopathy: semaglutide?acute pancreatitis ASCVD and HF benefit: canagliflozin, empagliflozin HF benefit: dapagliflozin ASCVD benefit: liraglutide Benefit: canagliflozin, empagliflozin Macroalbuminuira benefit: liraglutide, semaglutide Loss Loss High High? Intermediate Joint pain?acute pancreatitis Potential HF risk: saxagliptin, alogliptin (FDA warning) Neutral Neutral High 12
Halting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More information2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists
WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationAntihyperglycemic Therapy in Type 2 Diabetes: What's Guiding Pharmacotherapy Choice?
Antihyperglycemic Therapy in Type 2 Diabetes: What's Guiding Pharmacotherapy Choice? Zach Weber, PharmD, BCPS, BCACP, CDE Live Activity Handout 4 slides per page Antihyperglycemic Therapy in Type 2 Diabetes:
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationQUESTION #2 QUESTION #4
DIABETES TREATMENT: AN UPDATE (2018) PHARMACIST AND PHARMACY TECHNICIAN OBJECTIVES Aesha Drozdowski, PharmD, BCPS, BCACP Assistant Professor of Pharmacy Practice Roseman University of Health Sciences College
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationTHE NEW-ISH DIABETES MEDICINES
THE NEW-ISH DIABETES MEDICINES Using GLP1s and SGLT2s FINANCIAL DISCLOSURES None Brent Jones, MD Endocrinology Madison Medical Affiliates January 31, 2019 OBJECTIVES Gain familiarity with GLP1 receptor
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationWITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE
UPDATE ON THE NEW DIABETES MEDICATIONS AND HOW TO INCORPORATE INTO YOUR PRACTICE Amy DeGueme, MD, ECNU Madison Medical Affiliates 3/15/19 WITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE Which ones to
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationEvaluating the Cardiovascular Benefits of Antidiabetic Medications
Evaluating the Cardiovascular Benefits of Antidiabetic Medications Target Audience: Pharmacists ACPE#: 0202-0000-18-054-L01-P Activity Type: Application-based Disclosures Stuart T. Haines has no relevant
More informationType 2 Diabetes: An Evidence Based Pharmacotherapy Update
Type 2 Diabetes: An Evidence Based Pharmacotherapy Update C. Wayne Weart, Pharm.D. South Carolina College of Pharmacy MUSC Campus MUSC Department of Family Medicine January 2019 Faculty Disclosure I do
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationOLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationWelcome to the PHASE Learning Community! October 31, 2018
Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line
More information